What are Radioligand therapy drugs?

Radioligand therapy drugs are pharmacologic agents that share a common mechanism (typically targeting PSMA (prostate-specific membrane antigen)). 0 are currently marketed, with 6 more in clinical development.

Radioligand therapy

0 marketed 4 in Phase 3 1 in Phase 2 1 in Phase 1

This page covers all Radioligand therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PSMA (prostate-specific membrane antigen), Somatostatin receptor 2 (SSTR2), CD147.

Targets

PSMA (prostate-specific membrane antigen) · Somatostatin receptor 2 (SSTR2) · CD147

Phase 3 pipeline (4)

177Lu-PSMA-I&T · Weill Medical College of Cornell University · Oncology
177Lu-PSMA-I&T is a radioligand therapy that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them.
177Lu-PMSA-617 · UNICANCER · Oncology
177Lu-PMSA-617 is a radioligand therapy that delivers lutetium-177 radiation directly to prostate cancer cells expressing PSMA, causing targeted cell death.
177Lu-DOTATATE · Erasmus Medical Center · Oncology
177Lu-DOTATATE is a radioligand therapy that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation to kill them.
Lu-177 PSMA-617 · Radboud University Medical Center · Oncology
Lu-177 PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them.

Phase 2 pipeline (1)

177Lu-PSMA · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Oncology
177Lu-PSMA is a radioligand therapy that delivers lutetium-177, a beta-emitting radioisotope, directly to prostate-specific membrane antigen (PSMA) on cancer cells, causing targeted cell death.

Phase 1 pipeline (1)

89Zr-CD147 · Sinotau Pharmaceutical Group · Oncology
Targeting CD147